Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy

Naoto Takahashi, Ikuo Miura, Yoshimi Kobayashi, Masaaki Kume, Tomoko Yoshioka, Wataru Otane, Kaori Ohtsubo, Kaoru Takahashi, Atsushi Kitabayashi, Yoshinari Kawabata, Makoto Hirokawa, Hirokazu Nishijima, Ryo Ichinohasama, John DeCoteau, Akira B. Miura, Ken Ichi Sawada

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

We describe a method for monitoring chronic myeloid leukemia (CML) patients treated with imatinib that uses fluorescence in situ hybridization (FISH) to detect BCR-ABL in peripheral blood (PB) granulocytes. First, we compared this method, termed Neutrophil-FISH, with interphase FISH (i-FISH) analysis of bone marrow (BM), i-FISH analysis of PB mononuclear cells, and conventional cytogenetic analysis (CCA) of BM in 30 consecutive CML patients. We found the percentage of BCR-ABL-positive neutrophils as determined by Neutrophil-FISH to correlate best with the percentage of Philadelphia chromosome-positive metaphases in the BM determined by CCA (y = 0.8818x + 5.7249; r2 = 0.968). We then performed a serial Neutrophil-FISH study of 10 chronic-phase CML patients treated with imatinib and found that the technique could clearly separate imatinib responders from nonresponders within 12 weeks of drug administration. There was a significant difference in the percentages of BCR-ABL-positive neutrophils between responder (mean ± SD, 18.2% ± 11.8%) and nonresponder (82.4% ± 5.1%) groups at 12 weeks (P < .0001, Student t test). Together with real-time quantitative polymerase chain reaction analysis, Neutrophil-FISH represents another useful method for monitoring CML patients during the primary myelosuppressive stage of imatinib therapy because it is a quick, simple, and reliable method for assessing cytogenetic response.

Original languageEnglish
Pages (from-to)235-241
Number of pages7
JournalInternational journal of hematology
Volume81
Issue number3
DOIs
Publication statusPublished - 2005 Apr

Keywords

  • BCR-ABL
  • Chronic myeloid leukemia (CML)
  • Fluorescence in situ hybridization (FISH)
  • Imatinib mesylate (Glivec, Gleevec)
  • Neutrophils

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy'. Together they form a unique fingerprint.

Cite this